---
title: "Ultragenyx Pharmaceutical Inc. (RARE.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RARE.US.md"
symbol: "RARE.US"
name: "Ultragenyx Pharmaceutical Inc."
industry: "Biotechnology"
datetime: "2026-05-20T17:04:14.348Z"
locales:
  - [en](https://longbridge.com/en/quote/RARE.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RARE.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RARE.US.md)
---

# Ultragenyx Pharmaceutical Inc. (RARE.US)

## Company Overview

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.ultragenyx.com](https://www.ultragenyx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: C (0.53)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 89 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 13.53% |  |
| Net Profit YoY | -10.87% |  |
| P/B Ratio | -9.35 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2207221611.45 |  |
| Revenue | 670000000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 1327.46% | A |
| Profit Margin | -90.90% | E |
| Gross Margin | -27.21% | E |
| Revenue YoY | 13.53% | B |
| Net Profit YoY | -10.87% | D |
| Total Assets YoY | -1.21% | D |
| Net Assets YoY | -251.41% | E |
| Cash Flow Margin | 81.61% | C |
| OCF YoY | 13.53% | B |
| Turnover | 0.51 | C |
| Gearing Ratio | 117.67% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Ultragenyx Pharmaceutical Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "13.53%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-10.87%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-9.35",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2207221611.45",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "670000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "1327.46%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-90.90%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-27.21%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "13.53%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-10.87%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.21%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-251.41%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "81.61%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "13.53%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.51",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "117.67%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.62 | 333/386 | - | - | - |
| PB | -9.35 | 523/386 | 260.18 | 23.95 | 18.89 |
| PS (TTM) | 3.29 | 75/386 | 5.39 | 4.57 | 3.50 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-20T04:00:00.000Z

Total Analysts: **19**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 12 | 63% |
| Overweight | 5 | 26% |
| Hold | 2 | 11% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 23.16 |
| Highest Target | 84.00 |
| Lowest Target | 25.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RARE.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RARE.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RARE.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RARE.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**